Salve Therapeutics

Current gene therapies are mostly limited to plasmid-based and Adeno-associated virus variants with inefficient response rates and limited use. Better viral delivery methods would expand the available pharmacopeia to produce precision medicines for intractable and incurable genetic diseases. We are building VirCAD (Virus Computer-Aided Design), an HPC-powered, cloud-accessible, AI/ML-capable bioCAD platform to mine, design, model and test new viral drugs for improved cell and gene therapies, vaccines, oncolytics, antibiotics and other categories. These modalities will treat the many inherited and acquired genetic disorders afflicting patients due to their therapeutic specificity, efficiency, and customizability

Biotechnology,high-performance computing,artificial intelligence,machine learning,biochemistry,virology,cell and gene therapies,and medicine

Salve therapeutics operates in the Biotechnology research industry.

Salve therapeutics's revenue is 11m - 100m

Salve therapeutics has 11 - 50 employees.